Schwab Charles Investment Management Inc. Has $3.90 Million Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

Schwab Charles Investment Management Inc. lowered its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 20.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 225,993 shares of the medical instruments supplier’s stock after selling 59,279 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.39% of OraSure Technologies worth $3,901,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Victory Capital Management Inc. acquired a new stake in shares of OraSure Technologies in the 1st quarter valued at approximately $100,000. BNP Paribas Arbitrage SA lifted its holdings in OraSure Technologies by 977.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 10,718 shares of the medical instruments supplier’s stock valued at $139,000 after purchasing an additional 9,723 shares during the last quarter. Mason Street Advisors LLC acquired a new stake in OraSure Technologies during the 1st quarter valued at $168,000. State of Alaska Department of Revenue lifted its holdings in OraSure Technologies by 85.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 11,401 shares of the medical instruments supplier’s stock valued at $196,000 after purchasing an additional 5,241 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in OraSure Technologies during the 1st quarter valued at $202,000. 92.95% of the stock is owned by hedge funds and other institutional investors.

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) opened at 20.37 on Friday. The company has a 50-day moving average price of $21.63 and a 200 day moving average price of $17.96. OraSure Technologies, Inc. has a 1-year low of $7.09 and a 1-year high of $23.01. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of 37.65 and a beta of 1.55.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. The firm had revenue of $40.18 million for the quarter, compared to analysts’ expectations of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.07 earnings per share. On average, equities research analysts predict that OraSure Technologies, Inc. will post $0.48 EPS for the current year.

In related news, CFO Ronald H. Spair sold 510,112 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $20.66, for a total value of $10,538,913.92. Following the completion of the sale, the chief financial officer now owns 208,606 shares in the company, valued at $4,309,799.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Anthony Zezzo II sold 72,916 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $21.26, for a total value of $1,550,194.16. Following the completion of the sale, the executive vice president now owns 218,326 shares of the company’s stock, valued at approximately $4,641,610.76. The disclosure for this sale can be found here. Insiders sold 717,601 shares of company stock valued at $14,977,398 in the last quarter. 6.40% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/27/orasure-technologies-inc-osur-shares-sold-by-schwab-charles-investment-management-inc.html.

Several equities research analysts have issued reports on OSUR shares. Stephens reaffirmed an “overweight” rating and set a $19.00 price target (up previously from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. BidaskClub cut OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Canaccord Genuity reiterated a “buy” rating and set a $22.00 price objective on shares of OraSure Technologies in a research report on Tuesday, September 19th. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research report on Saturday, September 9th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $23.00 price objective on shares of OraSure Technologies in a research report on Friday, October 20th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. OraSure Technologies presently has a consensus rating of “Buy” and a consensus price target of $18.21.

OraSure Technologies Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply